1-2 of 2
Peter Johnson
Close
Sort by
Journal Articles

A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Clinical Trials & Observations
Tycel J. Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S. Lossos, Pier Luigi Zinzani, Catherine Thieblemont, Wojciech Jurczak, Fred Zheng, Erica Rappold, Wanying Zhao, Ping Jiang, Peter Johnson
Journal: Blood Advances
Blood Adv (2024) 8 (4): 867–877.
https://doi.org/10.1182/bloodadvances.2023010648
Published: 2024
Includes: Supplemental data
Journal Articles

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma

Findlay Bewicke-Copley, Koorosh Korfi, Shamzah Araf, Brendan Hodkinson, Emil Kumar, Thomas Cummin, Margaret Ashton-Key, Sharon Barrans, Suzan van Hoppe, Cathy Burton, Mohamed Elshiekh, Simon Rule, Nicola Crosbie, Andrew Clear, Maria Calaminici, Hendrik Runge, Robert K. Hills, David W. Scott, Lisa M. Rimsza, Geetha Menon, Chulin Sha, John R. Davies, Ai Nagano, Andrew Davies, Daniel Painter, Alexandra Smith, John Gribben, Kikkeri N. Naresh, David R. Westhead, Jessica Okosun, Andrew Steele, Daniel J. Hodson, Sriram Balasubramanian, Peter Johnson, Jun Wang, Jude Fitzgibbon
Journal: Blood Advances
Blood Adv (2023) 7 (5): 845–855.
https://doi.org/10.1182/bloodadvances.2022007536
Published: 2023
Includes: Supplemental data